» Articles » PMID: 28512253

Infiltrating Myeloid Cells Exert Protumorigenic Actions Via Neutrophil Elastase

Overview
Journal Mol Cancer Res
Specialty Cell Biology
Date 2017 May 18
PMID 28512253
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Tissue infiltration and elevated peripheral circulation of granulocytic myeloid-derived cells is associated with poor outcomes in prostate cancer and other malignancies. Although myeloid-derived cells have the ability to suppress T-cell function, little is known about the direct impact of these innate cells on prostate tumor growth. Here, it is reported that granulocytic myeloid-derived suppressor cells (MDSC) are the predominant tumor-infiltrating cells in prostate cancer xenografts established in athymic nude mice. MDSCs significantly increased in number in the peripheral circulation as a function of xenograft growth and were successfully depleted by Gr-1 antibody treatment. Importantly, MDSC depletion significantly decreased xenograft growth. We hypothesized that granulocytic MDSCs might exert their protumorigenic actions in part through neutrophil elastase (), a serine protease released upon granulocyte activation. Indeed, it was determined that NE is expressed by infiltrating immune cells and is enzymatically active in prostate cancer xenografts and in prostate tumors of prostate-specific -null mice. Importantly, treatment with sivelestat, a small-molecule inhibitor specific for NE, significantly decreased xenograft growth, recapitulating the phenotype of Gr-1 MDSC depletion. Mechanistically, NE activated MAPK signaling and induced MAPK-dependent transcription of the proliferative gene in prostate cancer cells. Functionally, NE stimulated proliferation, migration, and invasion of prostate cancer cells IHC on human prostate cancer clinical biopsies revealed coexpression of NE and infiltrating CD33 MDSCs. This report suggests that MDSCs and NE are physiologically important mediators of prostate cancer progression and may serve as potential biomarkers and therapeutic targets. .

Citing Articles

The development for emerging biomarkers of lymphangioleiomyomatosis.

Huang L, Xiao Y, Yang L, Ren S Orphanet J Rare Dis. 2024; 19(1):445.

PMID: 39614360 PMC: 11605962. DOI: 10.1186/s13023-024-03455-9.


Silver nanoparticle induced immunogenic cell death can improve immunotherapy.

Sargsian A, Koutsoumpou X, Girmatsion H, Egil C, Buttiens K, Luci C J Nanobiotechnology. 2024; 22(1):691.

PMID: 39523339 PMC: 11552147. DOI: 10.1186/s12951-024-02951-1.


3D DNAzyme Motor Nanodevice With Self-Powered FRET Amplifier and Self-Supplied HO for Enhancing Human Neutrophil Elastase Profiling and Chemodynamic Therapy in Lung Tumor.

Du H, Xu E, Xu Y, Xue Q, Xu H, Song J Adv Sci (Weinh). 2024; 11(44):e2406599.

PMID: 39348241 PMC: 11600284. DOI: 10.1002/advs.202406599.


Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies.

Zhang M, Qin H, Wu Y, Gao Q Cancer Biol Med. 2024; 21(10).

PMID: 39297568 PMC: 11523270. DOI: 10.20892/j.issn.2095-3941.2024.0192.


Impact of obesity‑associated myeloid‑derived suppressor cells on cancer risk and progression (Review).

Jimenez-Cortegana C, Gutierrez-Garcia C, Sanchez-Jimenez F, Vilarino-Garcia T, Flores-Campos R, Perez-Perez A Int J Oncol. 2024; 65(2).

PMID: 38940351 PMC: 11251741. DOI: 10.3892/ijo.2024.5667.


References
1.
Cedervall J, Zhang Y, Huang H, Zhang L, Femel J, Dimberg A . Neutrophil Extracellular Traps Accumulate in Peripheral Blood Vessels and Compromise Organ Function in Tumor-Bearing Animals. Cancer Res. 2015; 75(13):2653-62. DOI: 10.1158/0008-5472.CAN-14-3299. View

2.
Araki H, Pang X, Komatsu N, Soejima M, Miyata N, Takaki M . Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients. Cancer Immunol Immunother. 2015; 64(12):1565-73. PMC: 11028849. DOI: 10.1007/s00262-015-1756-7. View

3.
Cools-Lartigue J, Spicer J, Najmeh S, Ferri L . Neutrophil extracellular traps in cancer progression. Cell Mol Life Sci. 2014; 71(21):4179-94. PMC: 7096049. DOI: 10.1007/s00018-014-1683-3. View

4.
Gurel B, Lucia M, Thompson Jr I, Goodman P, Tangen C, Kristal A . Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):847-56. PMC: 4012292. DOI: 10.1158/1055-9965.EPI-13-1126. View

5.
Marvel D, Gabrilovich D . Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125(9):3356-64. PMC: 4588239. DOI: 10.1172/JCI80005. View